Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network

Pasoon Hellamand; Marleen G H Van de Sande; Lykke Midtbøll Ørnbjerg; Thomas Klausch; Michael Nurmohamed; R Van Vollenhoven; D.C. Nordström; Anna-Mari Hokkanen; MJ Santos; Elsa Vieira-Sousa; A. G. Loft; Bente Glintborg; Merete Lund Hetland; U Lindström; Johan Karlsson Wallman; Martin Michelsen; Adrian Ciurea; Michael J Nissen; Catalin Codreanu; C Moogosan; Gary J Macfarlane; Gareth T Jones; Karin Laas; Z Roter; M Tomsic; I Castrejon; M Pombo-Suarez; B Gudbjörnsson; Arni Jon Geirsson; Eirik K. Kristianslund; Jirí Vencovský; Lucie Nekvindova; B Zengin; Seth Guller; Mikkel Østergaard; I Van der Horst- Bruinsma

Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network

Pasoon Hellamand, Marleen G H Van de Sande, Lykke Midtbøll Ørnbjerg, Thomas Klausch, Michael Nurmohamed, R Van Vollenhoven, D.C. Nordström, Anna-Mari Hokkanen, MJ Santos, Elsa Vieira-Sousa, A. G. Loft, Bente Glintborg, Merete Lund Hetland, U Lindström, Johan Karlsson Wallman, Martin Michelsen, Adrian Ciurea, Michael J Nissen, Catalin Codreanu, C MoogosanGary J Macfarlane, Gareth T Jones, Karin Laas, Z Roter, M Tomsic, I Castrejon, M Pombo-Suarez, B Gudbjörnsson, Arni Jon Geirsson, Eirik K. Kristianslund, Jirí Vencovský, Lucie Nekvindova, B Zengin, Seth Guller, Mikkel Østergaard, I Van der Horst- Bruinsma

Abstract

Background:
Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis). Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

Original language	English
Journal	RMD Open
Volume	9(4): e003325
Pages (from-to)	RMD Open 9(4): e003325
ISSN	2056-5933
Publication status	Published - 2023

Fingerprint

Dive into the research topics of 'Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network'. Together they form a unique fingerprint.

Cite this

Hellamand, P., Van de Sande, M. G. H., Ørnbjerg, L. M., Klausch, T., Nurmohamed, M., Van Vollenhoven, R., Nordström, D. C., Hokkanen, A.-M., Santos, MJ., Vieira-Sousa, E., Loft, A. G., Glintborg, B., Hetland, M. L., Lindström, U., Wallman, J. K., Michelsen, M., Ciurea, A., Nissen, M. J., Codreanu, C., ... Van der Horst- Bruinsma, I. (2023). Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network. RMD Open, 9(4): e003325, RMD Open 9(4): e003325.

Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network. / Hellamand, Pasoon; Van de Sande, Marleen G H; Ørnbjerg, Lykke Midtbøll et al.
In: RMD Open, Vol. 9(4): e003325, 2023, p. RMD Open 9(4): e003325.

Research output: Contribution to journal › Journal article › Research › peer-review

Hellamand, P, Van de Sande, MGH, Ørnbjerg, LM, Klausch, T, Nurmohamed, M, Van Vollenhoven, R, Nordström, DC, Hokkanen, A-M, Santos, MJ, Vieira-Sousa, E, Loft, AG, Glintborg, B , Hetland, ML, Lindström, U, Wallman, JK, Michelsen, M, Ciurea, A, Nissen, MJ, Codreanu, C, Moogosan, C, Macfarlane, GJ, Jones, GT, Laas, K, Roter, Z, Tomsic, M, Castrejon, I, Pombo-Suarez, M, Gudbjörnsson, B, Geirsson, AJ, Kristianslund, EK, Vencovský, J, Nekvindova, L, Zengin, B, Guller, S, Østergaard, M & Van der Horst- Bruinsma, I 2023, 'Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network', RMD Open, vol. 9(4): e003325, pp. RMD Open 9(4): e003325.

Hellamand, Pasoon ; Van de Sande, Marleen G H ; Ørnbjerg, Lykke Midtbøll et al. / Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network. In: RMD Open. 2023 ; Vol. 9(4): e003325. pp. RMD Open 9(4): e003325.

@article{ba3b608fd99f49a19a9b4f9d0a047d8c,

title = "Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network",

abstract = "Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis). Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.",

author = "Pasoon Hellamand and {Van de Sande}, {Marleen G H} and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Thomas Klausch and Michael Nurmohamed and {Van Vollenhoven}, R and D.C. Nordstr{\"o}m and Anna-Mari Hokkanen and MJ Santos and Elsa Vieira-Sousa and Loft, {A. G.} and Bente Glintborg and Hetland, {Merete Lund} and U Lindstr{\"o}m and Wallman, {Johan Karlsson} and Martin Michelsen and Adrian Ciurea and Nissen, {Michael J} and Catalin Codreanu and C Moogosan and Macfarlane, {Gary J} and Jones, {Gareth T} and Karin Laas and Z Roter and M Tomsic and I Castrejon and M Pombo-Suarez and B Gudbj{\"o}rnsson and Geirsson, {Arni Jon} and Kristianslund, {Eirik K.} and Jir{\'i} Vencovsk{\'y} and Lucie Nekvindova and B Zengin and Seth Guller and Mikkel {\O}stergaard and {Van der Horst- Bruinsma}, I",

note = "COPECARE",

year = "2023",

language = "English",

volume = "9(4): e003325",

pages = "RMD Open 9(4): e003325",

journal = "RMD Open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the European spondyloarthritis (EuroSpA) research collaboration network

AU - Hellamand, Pasoon

AU - Van de Sande, Marleen G H

AU - Ørnbjerg, Lykke Midtbøll

AU - Klausch, Thomas

AU - Nurmohamed, Michael

AU - Van Vollenhoven, R

AU - Nordström, D.C.

AU - Hokkanen, Anna-Mari

AU - Santos, MJ

AU - Vieira-Sousa, Elsa

AU - Loft, A. G.

AU - Glintborg, Bente

AU - Hetland, Merete Lund

AU - Lindström, U

AU - Wallman, Johan Karlsson

AU - Michelsen, Martin

AU - Ciurea, Adrian

AU - Nissen, Michael J

AU - Codreanu, Catalin

AU - Moogosan, C

AU - Macfarlane, Gary J

AU - Jones, Gareth T

AU - Laas, Karin

AU - Roter, Z

AU - Tomsic, M

AU - Castrejon, I

AU - Pombo-Suarez, M

AU - Gudbjörnsson, B

AU - Geirsson, Arni Jon

AU - Kristianslund, Eirik K.

AU - Vencovský, Jirí

AU - Nekvindova, Lucie

AU - Zengin, B

AU - Guller, Seth

AU - Østergaard, Mikkel

AU - Van der Horst- Bruinsma, I

N1 - COPECARE

PY - 2023

Y1 - 2023

N2 - Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis). Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

AB - Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis). Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

M3 - Journal article

SN - 2056-5933

VL - 9(4): e003325

SP - RMD Open 9(4): e003325

JO - RMD Open

JF - RMD Open

ER -